Weiss Ratings Reiterates Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (d-)" rating reissued by equities research analysts at Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

Several other brokerages also recently weighed in on FDMT. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday, January 13th. Bank of America reduced their target price on 4D Molecular Therapeutics from $79.00 to $46.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Chardan Capital reaffirmed a "buy" rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Royal Bank of Canada dropped their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating for the company in a research note on Thursday, November 14th. Finally, Morgan Stanley dropped their target price on 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating for the company in a report on Monday, January 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, 4D Molecular Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $38.56.

4D Molecular Therapeutics Trading Down 8.4 %

NASDAQ FDMT traded down $0.55 on Friday, hitting $5.97. 2,072,632 shares of the company traded hands, compared to its average volume of 861,369. 4D Molecular Therapeutics has a 52-week low of $4.43 and a 52-week high of $36.25. The company has a market capitalization of $275.99 million, a price-to-earnings ratio of -2.09 and a beta of 2.81. The business's 50 day moving average price is $5.84 and its 200-day moving average price is $9.87.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC purchased a new position in shares of 4D Molecular Therapeutics in the 3rd quarter valued at $40,000. PNC Financial Services Group Inc. raised its stake in 4D Molecular Therapeutics by 66.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock valued at $51,000 after buying an additional 3,630 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in 4D Molecular Therapeutics by 5,291.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock worth $55,000 after acquiring an additional 9,737 shares in the last quarter. Values First Advisors Inc. acquired a new stake in 4D Molecular Therapeutics in the 3rd quarter worth approximately $57,000. Finally, AlphaQuest LLC lifted its stake in shares of 4D Molecular Therapeutics by 3,665.2% during the fourth quarter. AlphaQuest LLC now owns 14,835 shares of the company's stock worth $83,000 after buying an additional 14,441 shares during the period. Hedge funds and other institutional investors own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.